Perfil del autor: Merino Bohórquez, Vicente
Datos institucionales
Nombre | Merino Bohórquez, Vicente |
Departamento | Farmacología |
Área de conocimiento | Farmacología |
Categoría profesional | Profesor Asociado CIS |
Correo electrónico | Solicitar |
Estadísticas
-
Nº publicaciones
23
-
Nº visitas
1842
-
Nº descargas
2646
Publicaciones |
---|
Tesis Doctoral
Farmacocinética y farmacodinamia de piperacilina/tazobactam y fosfomicina en pacientes con bacteriemia por enterobacteriaceae
(2024)
En esta tesis se aborda el estudio de la farmacocinética y farmacodinamia de dos antimicrobianos en bacteriemias por ... |
Artículo
Evaluation of temocillin efficacy against KPC-2-producing Klebsiella pneumoniae isolates in a hollow-fibre infection model
(Oxford University Press, 2024)
Background: Temocillin is an old antimicrobial that is resistant to hydrolysis by ESBLs but has variable activity against ... |
Artículo
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
(ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2024)
Background/aims: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could ... |
Artículo
Patient-reported outcome measures in severe asthma: an expert consensus
(Taylor and Francis Group, 2023)
Objective The study aimed to reach a consensus on the most relevant patient-reported outcomes (PROs), the corresponding ... |
Artículo
Performance of a Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA
(Springer, 2023)
Background Therapeutic drug monitoring of infliximab levels in patients with inflammatory bowel disease (IBD) optimizes ... |
Trabajo Fin de Grado
Comparación entre la prueba rápida Point of Care (POC) y un método de referencia ELISA para la monitorización terapéutica de infliximab y adalimumab en enfermedad inflamatoria intestinal
(2023)
INTRODUCCIÓN: La monitorización terapéutica (TDM) de infliximab (IFX) y adalimumab (ADL) en pacientes con enfermedad ... |
Artículo
Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
(MDPI, 2023)
Pseudoxanthoma elasticum (PXE) is characterized by low levels of inorganic pyrophosphate (PPi) and a high activity of ... |
Artículo
Association between HLA DNA variants and long-term response to anti-TNF drugs in a Spanish pediatric inflammatory bowel disease cohort
(MDPI, 2023)
The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated with the response to anti-TNF treatment ... |
Artículo
Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections A Randomized Clinical Trial
(Jama Nerwork Open, 2022)
Importance The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant ... |
Trabajo Fin de Grado
Eficacia y seguridad en vida real de fármacos sintéticos dirigidos en artritis reumatoide
(2022)
Introducción: La artritis reumatoide es una patología reumática caracterizada por la inflamación de una o más articulaciones, ... |
Trabajo Fin de Grado
Efectividad y seguridad de los anticuerpos monoclonales en el tratamiento preventivo de la migraña
(2021)
La migraña es una enfermedad de gran relevancia en la población, especialmente en mujeres. Es de origen neurovascular y ... |
Artículo
Population pharmacokinetics of piperacillin in non-critically ill patients with bacteremia caused by enterobacteriaceae
(MDPI, 2021)
This study analyzes the pharmacokinetic variability of piperacillin in non-critically ill patients with Enterobacteriaceae ... |
Artículo
Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease
(MDPI, 2021)
Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis ... |
Artículo
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial
(BMJ Publishing Group, 2021)
Introduction: Alternatives to carbapenems are needed in the treatment of third-generation cephalosporin-resistant ... |
Artículo
Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease
(MDPI, 2020)
Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs ... |
Artículo
Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice
(Aran Ediciones S.A., 2020)
Introduction: between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Ther apeutic ... |
Artículo
Preparation and Characterization of New Liposomes. Bactericidal Activity of Cefepime Encapsulated into Cationic Liposomes
(MDPI, 2019)
Cefepime is an antibiotic with a broad spectrum of antimicrobial activity. However, this antibiotic has several side effects ... |
Artículo
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
(Original Research, 2019)
Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated ... |
Artículo
A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy
(Wiley, 2018)
We describe a case of one patient with cystic fibrosis who developed a pan-resistant Burkholderia cepacia complex rapidly ... |
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
(Aran Ediciones S.A., 2018)
Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of ... |
Artículo
Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli
(Elsevier, 2018)
Objectives: To describe the population pharmacokinetics of fosfomycin for patients with bacteraemic urinary tract infection ... |
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory ... |
Artículo
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial
(BMJ Publishing Group, 2015)
Introduction Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing ... |